MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$301K
Free Cash flow
-$6,134K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Issuance of common stock to rela...
Accrued expenses
Stock-based compensation
Others
Negative Cash Flow Breakdown
Accounts payable
Gain on derecognition of contrac...
Payments on insurancepremiumloan
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-6,370
-6,780
-6,633
-6,530
Depreciation and amortization
-
130
115
105
Depreciation
258
-
-
-
Stock-based compensation
313
312
467
276
Reclassification of foreign currency translation adjustments
-
-
117
-
Equipment write-off and loss on equipment disposal
-
-
0
-
Non-cash lease expense
28
34
116
39
Fixed assets write-off
-
-
-
0
Gain on derecognition of contract liabilities
335
-
-
-
R&d tax credit incentive receivable
12
43
-10
170
Prepaid expenses and other assets
-76
141
154
-650
Accounts payable
-397
433
-396
-759
Accrued compensation expenses
-32
-16
8
1
Accrued expenses
566
-125
-135
37
Net cash used in operating activities
-6,035
-6,196
-6,719
-6,351
Purchases of property and equipment
99
3
274
823
Net cash used in investing activities
-99
-3
-274
-823
Proceeds from issuance of common stock and warrants in connection with securities purchase agreement, net of issuance costs
-
-
0
0
Proceeds from issuance of common stock in connection with the sales agreement, net of issuance costs
-
-
-28
-
Proceeds from issuance of common stock in connection with director private securities purchase agreement, net of issuance costs
-
-
0
-
Proceeds from issuance of common stock in connection with 2025 private sales transaction, net of issuance costs
-
-
8,543
-
Issuance of common stock to related party in connection with 2025 private sales transactions, net
5,939
5,650
-
-
Issuance of common stock in connection with 2026 registered direct offering, net
0
2,174
8,748
-
Issuance of common stock in connection with the 2025 private sales transaction, net of issuance costs
-
-
-
2,593
Issuance of common stock to related party in connection with 2026 private placement, net
0
1,997
6,000
-
Gross proceeds from insurance premium loan
-
-
0
355
Payments on insurancepremiumloan
-106
-107
-107
0
Net proceeds from issuance of common stock in connection with the sales agreement, net of issuance costs
-
-
-
-28
Net issuance costs in connection with the sales agreement
0
0
-
-
Net cash provided by (used in) financing activities
5,833
9,714
20,591
2,948
Effect of exchange rate changes on cash and cash equivalents
0
2
6
60
Net increase (decrease) in cash, cash equivalents and restricted cash
-301
3,517
13,604
-4,166
Cash, cash equivalents and restricted cash balance at beginning of period
21,087
17,570
3,966
19,690
Cash, cash equivalents and restricted cash balance at end of period
20,786
21,087
17,570
3,966
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Issuance of common stock
to related party in...
$5,939K
Net cash provided by
(used in) financing...
$5,833K
(2301.13%↑ Y/Y)
Canceled cashflow
$106K
Net increase
(decrease) in cash, cash...
-$301K
(97.40%↑ Y/Y)
Canceled cashflow
$5,833K
Accrued expenses
$566K
(2730.00%↑ Y/Y)
Stock-based compensation
$313K
(-57.76%↓ Y/Y)
Depreciation
$258K
Prepaid expenses and
other assets
-$76K
(81.55%↑ Y/Y)
Non-cash lease expense
$28K
(-75.44%↓ Y/Y)
Payments on
insurancepremiumloan
-$106K
(55.27%↑ Y/Y)
Net cash used in
operating activities
-$6,035K
(46.36%↑ Y/Y)
Canceled cashflow
$1,241K
Net cash used in
investing activities
-$99K
(-30.26%↓ Y/Y)
Net loss
-$6,370K
(52.63%↑ Y/Y)
Accounts payable
-$397K
(-142.55%↓ Y/Y)
Gain on
derecognition of contract...
$335K
Accrued compensation
expenses
-$32K
(-346.15%↓ Y/Y)
R&d tax credit
incentive receivable
$12K
(-95.02%↓ Y/Y)
Purchases of property and
equipment
$99K
(30.26%↑ Y/Y)
Buy us a coffee
Vivani Medical, Inc. (VANI)
Vivani Medical, Inc. (VANI)